Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1421-9794|60|4|267-273

ISSN： 0009-3157

Source： Chemotherapy, Vol.60, Iss.4, 2015-04, pp. : 267-273

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 56, Iss. 5, 2010-10 ,pp. : 353-358

Karger

Access to resources Recommend Favorite

A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 78-83

Karger

Access to resources Recommend Favorite

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

By  

Chemotherapy, Vol. 61, Iss. 1, 2015-0 ,pp. : 41-50

Karger

Access to resources Recommend Favorite

A Randomized Phase II Trial of Gemcitabine plus Carboplatin: Biweekly versus Standard Schedules in Patients with Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 346-353

Karger

Access to resources Recommend Favorite

Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-04 ,pp. : 205-213

Karger

Access to resources Recommend Favorite